ProCE Banner Activity

Current Essential Testing in Early Breast Cancer: A Focus on BRCA Testing and Adjuvant PARP Inhibition

Clinical Thought
BRCA testing is now essential to identify patients with early breast cancer who may benefit from adjuvant olaparib.

Released: November 17, 2022

Expiration: November 16, 2023

No longer available for credit.

Share

Faculty

Charles E. Geyer, Jr.

Charles E. Geyer, Jr., MD

Professor of Medicine
Division of Hematology/Medical Oncology
Department of Internal Medicine
University of Pittsburgh UPMC Hillman Cancer Center
Staff Attending
Breast Medical Oncology
UPMC Magee Womens Hospital
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

ProCE

ProCE Banner

Faculty Disclosure

Primary Author

Charles E. Geyer, Jr., MD

Professor of Medicine
Division of Hematology/Medical Oncology
Department of Internal Medicine
University of Pittsburgh UPMC Hillman Cancer Center
Staff Attending
Breast Medical Oncology
UPMC Magee Womens Hospital
Pittsburgh, Pennsylvania

Charles E. Geyer, Jr., MD: researcher: AbbVie, AstraZeneca, Daiichi Sankyo, Roche/Genentech; consultant/advisor/speaker: Exact Sciences, SeaGen.